Severe bullous hypersensitivity reactions after exposure to carbamazepine in a han-chinese child with a positive HLAB* 1502 and negative in vitro toxicity assays: Evidence for different pathophysiological mechanisms

Canadian Journal of Clinical Pharmacology

Volumn 18, Issue 1, 2011, Pages

  Elzagallaai, Abdelbaset A ^a,b   Garcia Bournissen, Facundo ^e   Finkelstein, Yaron ^e,f   Bend, John R ^c,d   Rieder, Michael J ^b   Koren, Gideon ^a,b,e  

^a Ivey Chair in Molecular Toxicology   (Canada)

^b Department of Physiology and Pharmacology ^*  (Canada)

^c WESTERN UNIVERSITY   (Canada)

^d UNIVERSITY OF WESTERN ONTARIO   (Canada)

^e HOSPITAL FOR SICK CHILDREN   (Canada)

^f BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Adverse drug reactions; Drug hypersensitivity syndrome; Drug induced stevens johnson syndrome; In vitro diagnosis; In vitro toxicity assay

Indexed keywords

CARBAMAZEPINE; CORTICOSTEROID; HLA B ANTIGEN; IMMUNOGLOBULIN; PHENOBARBITAL;

ARTICLE; BLISTER; BULLOUS HYPERSENSITIVITY REACTION; CASE REPORT; CAUCASIAN; CELL ASSAY; CHILD; CHINESE; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRESS SYNDROME; DRUG INDUCED DISEASE; EPIDERMOLYSIS BULLOSA; EPILEPSY; ERYTHEMA; FEVER; GENETIC ASSOCIATION; HAN CHINESE; HUMAN; LYMPHOCYTOTOXICITY; MACULOPAPULAR RASH; MALE; PATHOPHYSIOLOGY; PHENOTYPE; RASH; SCHOOL CHILD; STEVENS JOHNSON SYNDROME; THROMBOCYTE;

EID: 79251602698     PISSN: 1198581X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Rawlins M, Thompson J. Mechanisms of adverse drug reactions. In: Davies D, editor. Textbook of adverse drug reactions. Oxford: Oxford University Press; 1991. p. 18-45.
2. Uetrecht J. Idiosyncratic drug reactions: current understanding. Annu Rev Pharmacol Toxicol 2007; 47:513-39.
3. Demoly P, Viola M, Rebelo Gomes E, Romano A. Epidemiology and Causes of Drug Hypersensitivity. In: Pichler W, editor. Drug Hypersensitivity. Basel: Karger; 2007. p. 2-17.
4. Hunziker T, Bruppacher R, Kuenzi UP, et al. Classification of ADRs: a proposal for harmonization and differentiation based on the experience of the Comprehensive Hospital Drug Monitoring Bern/St. Gallen, 1974-1993. Pharmacoepidemiol Drug Saf 2002;11:159-63.
5. Zaccara G, Franciotta D, Perucca E. Idiosyncratic adverse reactions to antiepileptic drugs. Epilepsia 2007;48:1223-44.
6. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994; 331:1272-85.
7. Teraki Y, Shibuya M, Izaki S. Stevens-Johnson syndrome and toxic epidermal necrolysis due to anticonvulsants share certain clinical and laboratory features with drug-induced hypersensitivity syndrome, despite differences in cutaneous presentations. Clin Exp Dermatol 2010;35(7):723-8.
8. Wolf R, Matz H, Marcos B, Orion E. Drug rash with eosinophilia and systemic symptoms vs.toxic epidermal necrolysis: the dilemma of classification. Clin Dermatol 2005;23:311-4.
9. Shear NH, Spielberg SP. Anticonvulsant hypersensitivity syndrome. In vitro assessment of risk. J Clin Invest 1988;82:1826-32.
10. Knowles SR, Uetrecht J, Shear NH. Idiosyncratic drug reactions: the reactive metabolite syndromes. Lancet 2000;356:1587-91.
11. Spielberg SP, Gordon GB, Blake DA, Goldstein DA, Herlong HF. Predisposition to phenytoin hepatotoxicity assessed in vitro. N Engl J Med 1981;305:722-7.
12. Gennis MA, Vemuri R, Burns EA, Hill JV, Miller MA, Spielberg SP. Familial occurrence of hypersensitivity to phenytoin. Am J Med 1991;91:631-4.
13. Chung WH, Hung SI, Hong HS, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004;428:486.
14. Mallal S, Nolan D, Witt C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002;359:727-32.
15. Hung SI, Chung WH, Jee SH, et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genomics 2006;16:297-306.
16. Ferrell PB, Jr., McLeod HL. Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. Pharmacogenomics 2008;9:1543-6.
17. Franciotta D, Kwan P, Perucca E. Genetic basis for idiosyncratic reactions to antiepileptic drugs. Curr Opin Neurol 2009;22:144-9.
18. Alfirevic A, Jorgensen AL, Williamson PR, Chadwick DW, Park BK, Pirmohamed M. HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. Pharmacogenomics 2006;7:813-8.
19. Kano Y, Hirahara K, Asano Y, Shiohara T. HLA-B allele associations with certain drugs are not confirmed in Japanese patients with severe cutaneous drug reactions. Acta Derm Venereol 2008;88:616-8.
20. Lonjou C, Thomas L, Borot N, et al. A marker for Stevens-Johnson syndrome: ethnicity matters. Pharmacogenomics J 2006;6:265-8.
21. Leeder JS. Mechanisms of idiosyncratic hypersensitivity reactions to antiepileptic drugs. Epilepsia 1998;39 Suppl 7:S8-16.
22. Wu Y, Sanderson JP, Farrell J, et al. Activation of T cells by carbamazepine and carbamazepine metabolites. J Allergy Clin Immunol 2006; 118:233-41.
23. Naisbitt DJ, Britschgi M, Wong G, et al. Hypersensitivity reactions to carbamazepine: characterization of the specificity, phenotype, and cytokine profile of drug-specific T cell clones. Mol Pharmacol 2003; 63:732-41.
24. Elzagallaai AA, Knowles SR, Rieder MJ, Bend JR, Shear NH, Koren G. Patch testing for the diagnosis of anticonvulsant hypersensitivity syndrome: a systematic review. Drug Saf 2009;32:391-408.
25. Lee AY, Choi J, Chey WY. Patch testing with carbamazepine and its main metabolite carbamazepine epoxide in cutaneous adverse drug reactions to carbamazepine. Contact Dermatitis 2003;48:137-9.
26. Wu Y, Farrell J, Pirmohamed M, Park BK, Naisbitt DJ. Generation and characterization of antigen-specific CD4+, CD8+, and CD4+CD8+ T-cell clones from patients with carbamazepine hypersensitivity. J Allergy Clin Immunol 2007;119:973-81.
27. Chung WH, Hung SI, Chen YT. Genetic predisposition of life-threatening antiepilepticinduced skin reactions. Expert Opin Drug Saf 2010;9:15-21.
28. Pirmohamed M. Genetic factors in the predisposition to drug-induced hypersensitivity reactions. AAPS J 2006;8:E20-6.
29. Phillips EJ, Mallal SA. HLA and drug-induced toxicity. Curr Opin Mol Ther 2009; 11:231-42.
30. Harr T, French LE. Severe cutaneous adverse reactions: acute generalized exanthematous pustulosis, toxic epidermal necrolysis and Stevens-Johnson syndrome. Med Clin North Am; 2010 Jul;94(4):727-42, x.
31. Knowles SR, Shear NH. Recognition and management of severe cutaneous drug reactions. Dermatol Clin 2007;25:245-53, viii.
32. Landsteiner K, Jacobs J. Studies on the Sensitization of Animals with Simple Chemical Compounds. J Exp Med 1935;61:643-56.
33. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994; 12:991-1045.
34. Pichler WJ. Pharmacological interaction of drugs with antigen-specific immune receptors: the p-i concept. Curr Opin Allergy Clin Immunol 2002;2:301-5.
35. Ju C, Uetrecht JP. Mechanism of idiosyncratic drug reactions: reactive metabolite formation, protein binding and the regulation of the immune system. Curr Drug Metab 2002;3:367-77.
36. Rieder MJ, Uetrecht J, Shear NH, Cannon M, Miller M, Spielberg SP. Diagnosis of sulfonamide hypersensitivity reactions by invitro rechallenge with hydroxylamine metabolites. Ann Intern Med 1989;110:286-9.
37. Elzagallaai AA, Rieder MJ, Koren G. The In vitro Platelet Toxicity Assay (iPTA): a novel approach for assessment of drug hypersensitivity syndrome. J Clin Pharm 2010; in press.
38. Wang G, Konig R, Ansari GA, Khan MF. Lipid peroxidation-derived aldehyde-protein adducts contribute to trichloroethene-mediated autoimmunity via activation of CD4+ T cells. Free Radic Biol Med 2008;44:1475-82.
39. Rieder MJ. Immune mediation of hypersensitivity adverse drug reactions: implications for therapy. Expert Opin Drug Saf 2009;8:331-43.
40. Naisbitt DJ, Pirmohamed M, Park BK. Immunological principles of T-cell-mediated adverse drug reactions in skin. Expert Opin Drug Saf 2007;6:109-24.
41. Pichler WJ, Adam J, Daubner B, Gentinetta T, Keller M, Yerly D. Drug hypersensitivity reactions: pathomechanism and clinical symptoms. Med Clin North Am;94:645-64, xv.
42. Posadas SJ, Padial A, Torres MJ, et al. Delayed reactions to drugs show levels of perforin, granzyme B, and Fas-L to be related to disease severity. J Allergy Clin Immunol 2002;109:155-61.
43. Hausmann O, Schnyder B, Pichler WJ. Drug hypersensitivity reactions involving skin. In: Uetrecht J, editor. Adverse Drug Reactions, Hand book of Experimental Pharmacology. Berlin: Springer-Verlag; 2010. p. 30-52.
44. Uetrecht J. Immune-mediated adverse drug reactions. Chem Res Toxicol 2009;22:24-34.
45. Commbs P, Gell P. Classification of allergic reactions responsible for clinical hypersensitivity and disease. In: RR G, editor. Clinical aspects of immunology. Oxford: Oxford University Press; 1968. p. 575-96.
46. Rodriguez-Pena R, Antunez C, Martin E, Blanca-Lopez N, Mayorga C, Torres MJ. Allergic reactions to beta-lactams. Expert Opin Drug Saf 2006;5:31-48.
47. Pichler WJ. Delayed drug hypersensitivity reactions. Ann Intern Med 2003;139:683-93.
48. Elzagallaai AA, Knowles SR, Rieder MJ, Bend JR, Shear NH, Koren G. In vitro testing for the diagnosis of anticonvulsant hypersensitivity syndrome: a systematic review. Mol Diagn Ther 2009;13:313-30.
49. Shiohara T, Inaoka M, Kano Y. Drug-induced hypersensitivity syndrome (DIHS): a reaction induced by a complex interplay among herpes viruses and antiviral and antidrug immune responses. Allergol Int 2006;55:1-8.
50. Shiohara T, Iijima M, Ikezawa Z, Hashimoto K. The diagnosis of a DRESS syndrome has been sufficiently established on the basis of typical clinical features and viral reactivations. Br J Dermatol 2007;156:1083-4.
51. Gerber BO, Pichler WJ. The p-i concept: Evidence and implications. In: Pichler WJ, editor. Drug Hypersensitivity. Basel: Karger; 2007. p. 66-73.